Montreal's ProMetic BioTherapeutics Inc has entered a strategic alliance with Taiwan's Blue Blood Biotech Corp to develop drugs derived from human plasma and utilizing ProMetic's proprietary manufacturing process. Blue Blood and ProMetic BioTherapeutics, a subsidiary of ProMetic Life Sciences Inc, will share in revenues projected at $50 million annually. Production will initially focus on hyperimmune cytomega-lovirus aimed at the Taiwanese and Southeast Asian markets....